Results 71 to 80 of about 51,741 (305)

Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study [PDF]

, 2023
BACKGROUND: People with substance use disorder have a high risk of SARS-CoV-2 infection and subsequent poor outcomes. Few studies have evaluated COVID-19 vaccine effectiveness among people with substance use disorder.
Castle, David J, Chan, Esther W, Chang, Wing Chung, Chui, Celine SL, Chung, Albert KK, Cowling, Benjamin J, Hayes, Joseph F, Huang, Caige, Kang, Wei, Lai, Francisco TT, Lau, Chak Sing, Li, Xue, Shami, Jessica JP, Tse, Man Li, Wan, Eric YF, Wei, Yue, Wong, Carlos KH, Wong, Ian CK, Yan, Vincent KC, Ye, Xuxiao, Yiu, Hei Hang Edmund   +20 more
core  

Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines [PDF]

, 2023
IMPORTANCE: There is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and
Kragholm, Kristian Hay, Pareek, Manan, Polverino, Paolo, Sessa, Francesco, Sessa, Maurizio, Sessa, Pasquale   +5 more
core   +2 more sources

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

Human Vaccines & Immunotherapeutics, 2021
The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to ...
Michele Gringeri, Giulia Mosini, Vera Battini, Gianluca Cammarata, Greta Guarnieri, Carla Carnovale, Emilio Clementi, Sonia Radice   +7 more
doaj   +1 more source

Safety of BNT162b2 or CoronaVac COVID-19 vaccines in patients with heart failure: A self-controlled case series study [PDF]

, 2022
BACKGROUND: COVID-19 vaccines are important for patients with heart failure (HF) to prevent severe outcomes but the safety concerns could lead to vaccine hesitancy.
Chan, Esther W, Chui, Celine SL, Huang, Caige, Lai, Francisco TT, Li, Silvia TH, Li, Xue, Ma, Tiantian, Qin, Xiwen, Tse, Hung-Fat, Wan, Eric YF, Wei, Yue, Wong, Carlos KH, Wong, Ian CK, Yan, Vincent KC, Ye, Xuxiao, Yiu, Kai-Hang   +15 more
core   +1 more source

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Human Vaccines & Immunotherapeutics, 2023
In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously.
Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez, Eveline Pipolo Milan, Maria Cleonice Justino, Sagida Bibi, Parvinder Aley, Ralf Clemens, Andrew J. Pollard   +15 more
doaj   +1 more source

Early Real-World Data to Assess Benefits and Risks of COVID-19 Vaccines: A Systematic Review of Methods [PDF]

, 2022
Since the authorization of the first COVID-19 vaccines in December 2020, multiple studies using real-world data (RWD) have been published to assess their effectiveness/safety profile.
Herdeiro, Maria, Hernández-Muñoz, José, Ida, Fidelia, Plácido, Ana, Ribeiro, Tatiane, Roque, Fátima, Vu, Mai   +6 more
core   +1 more source

Eosinophilic cellulitis after BNT162b2 mRNA Covid‐19 vaccine [PDF]

Journal of the European Academy of Dermatology and Venereology, 2021
A 71-year-old woman with history of treated high blood pressure and atrial fibrillation presented with a painful eruption of the right arm and forearm. Symptoms started the day following the second dose of the BNT162b2 COVID-19 vaccine (Pfizer/BioNTech) with a localized injection site reaction that progressively worsened.
L. de Montjoye, L. Marot, M. Baeck
openaire   +3 more sources

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines

Infection and Drug Resistance, 2022
Naif Khalaf Alharbi,1,2 Jaffar A Al-Tawfiq,3– 5 Amal Alwehaibe,1 Mohamed W Alenazi,1 Abdulrahman Almasoud,1 Abdullah Algaisi,6 Fahad A Alhumaydhi,7 Anwar M Hashem,8,9 Mohammed Bosaeed,1,2,10 Suliman A Alsagaby11 1Vaccine Development Unit, King Abdullah ...
Alharbi NK, Al-Tawfiq JA, Alwehaibe A, Alenazi MW, Almasoud A, Algaisi A, Alhumaydhi FA, Hashem AM, Bosaeed M, Alsagaby SA   +9 more
doaj  

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response

Human Vaccines & Immunotherapeutics, 2021
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production.
Areti Tychala, Georgios Meletis, Eugenia Katsimpourlia, Ioanna Gkeka, Rodoula Dimitriadou, Eleni Sidiropoulou, Lemonia Skoura   +6 more
doaj   +1 more source

Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine

Cam & Sakura Medical Journal, 2023
Although thromboembolism after ChAdOx1 vaccine has been extensively reported, this association was rarely reported after vaccination with BNT162b2. We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia and ...
Ahmet Can Topçu, Abdurrahman Ekinci, Nihan Kayalar, Mehmed Yanartaş   +3 more
doaj   +1 more source